Jul 31, 2020 9:20am EDT Emerald Bioscience Announces Pricing of $7.0 Million Upsized Registered Offering
Jun 09, 2020 9:37am EDT Emerald Bioscience Announces Presentation of Cannabidiol-Valine-Hemisuccinate Ocular Data at Virtual ARVO® Meeting
Jun 02, 2020 8:30am EDT Emerald Bioscience Announces Awarding of Patent for Cannabidiol-Valine-Hemisuccinate in Japan
Mar 09, 2020 8:30am EDT Emerald Bioscience Announces Notice of Allowance from United States Patent Office for Proprietary Analog of Cannabidiol
Jan 30, 2020 8:30am EST Emerald Bioscience to Present at the 9th Annual Glaucoma 360 New Horizons Forum and BIO CEO & Investor Forum
Jan 13, 2020 8:30am EST Emerald Bioscience Provides Update on Recent Progress and Expected 2020 Milestones
Dec 10, 2019 8:30am EST Emerald Bioscience Inc. Announces Cannabidiol-Valine-Hemisuccinate Possesses Enhanced Anti-Seizure Activity when Compared with Cannabidiol (CBD) in the StemoniX Human Neural Tissue Platform
